Page 22 - IMO-2-1

Innovative Medicines & Omics Incretin mimetics in diabetes management

48. Jackson SH, Martin TS, Jones JD, Seal D, Emanuel F. 60. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight
Liraglutide (victoza): The first once-daily incretin mimetic loss effects of semaglutide in obesity without diabetes in the
injection for type-2 diabetes. P T. 2010;35(9):498-529. SELECT trial. Nat Med. 2024;30(7):2049-2057.
49. Liraglutide (Saxenda): CADTH Reimbursement Review: doi: 10.1038/s41591-024-02996-7
Therapeutic Area: Chronic Weight Management in Adults. 61. Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers
Ottawa (ON): Canadian Agency for Drugs and Technologies body weight in rodents via distributed neural pathways. JCI
in Health; 2021 Dec. Clinical Review. Available from: https:// Insight. 2020;5(6):e133429.
www.ncbi.nlm.nih.gov/books/NBK594336 [Last accessed
on 2024 Aug 23]. doi: 10.1172/jci.insight.133429
50. Scott LJ. Dulaglutide: A review in type 2 diabetes. Drugs. 62. Okamoto A, Yokokawa H, Nagamine T, Fukuda H, Hisaoka T,
2020;80(2):197-208. Naito T. Efficacy and safety of semaglutide in glycemic control,
body weight management, lipid profiles and other biomarkers
doi: 10.1007/s40265-020-01260-9
among obese type 2 diabetes patients initiated or switched to
51. Gao X, Di Y, Lv Y, et al. A pharmacokinetic study comparing semaglutide from other GLP-1 receptor agonists. J Diabetes
the biosimilar HEC14028 and Dulaglutide (Trulicity®) in Metab Disord. 2021;20:2121-2128.
healthy Chinese subjects. Clin Transl Sci. 2024;17(4):e13775.
doi: 10.1007/s40200-021-00899-9
doi: 10.1111/cts.13775
63. Tulp OL, Einstein GP. Review: Obesity and its associated
52. Arslanian SA, Hannon T, Zeitler P, et al. Once-weekly inflammatory cytokines pose significant risk factors for
dulaglutide for the treatment of youths with type 2 diabetes. COVID-19 outcomes. Adv Obes Weight Manag Control.
N Engl J Med. 2022;387(5):433-443. 2022;12(1):14-20.
doi: 10.1056/NEJMoa2204601 doi: 10.15406/aowmc.2022.12.00358
53. Wang Y, Deng F, Zhong X, et al. Dulaglutide provides 64. Andersen A, Knop FK, Vilsbøll T. A pharmacological and
protection against sepsis-induced lung injury in mice by clinical overview of oral semaglutide for the treatment of
inhibiting inflammation and apoptosis. Eur J Pharmacol. type 2 diabetes. Drugs. 2021;81(9):1003-1030.
2023;949:175730.
doi: 10.1007/s40265-021-01499-w
doi: 10.1016/j.ejphar.2023.175730
65. Lewis AL, McEntee N, Holland J, Patel A. Development and
54. Chaudhry H, Zhou J, Zhong Y, et al. Role of cytokines as a approval of rybelsus (oral semaglutide): Ushering in a new
double-edged sword in sepsis. In Vivo. 2013;27(6):669-684. era in peptide delivery. Drug Deliv Transl Res. 2022;12(1):1-6.
55. Wang R, Wang N, Han Y, Xu J, Xu Z. Dulaglutide alleviates doi: 10.1007/s13346-021-01000-w
LPS-induced injury in cardiomyocytes. ACS Omega. 66. Bucheit JD, Pamulapati LG, Carter N, Malloy K, Dixon DL,
2021;6(12):8271-8278.
Sisson EM. Oral semaglutide: A review of the first oral
doi: 10.1021/acsomega.0c06326 glucagon-like peptide 1 receptor agonist. Diabetes Technol
Ther. 2020;22(1):10-18.
56. Xie D, Li Y, Xu M, Zhao X, Chen M. Effects of dulaglutide
on endothelial progenitor cells and arterial elasticity in doi: 10.1089/dia.2019.0185
patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 67. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of
2022;21(1):200.
gastrointestinal adverse events associated with glucagon-
doi: 10.1186/s12933-022-01634-1 like peptide-1 receptor agonists for weight loss. JAMA.
2023;330(18):1795-1797.
57. Kommu S, Whitfield P. Semaglutide. In: StatPearls. Treasure
Island, FL: StatPearls Publishing; 2024. Available from : doi: 10.1001/jama.2023.19574
https://www.ncbi.nlm.nih.gov/books/NBK603723 [Last 68. Okeke IG, Camarda AR, Okeke R, Chaughtai S.
accessed on 2024 Aug 26].
Semaglutide-induced hyperemesis gravidarum. JCEM Case
58. Seidu S, Mellbin L, Kaiser M, Khunti K. Will oral semaglutide Rep. 2024;2(2):luad167.
be a game-changer in the management of type 2 diabetes in doi: 10.1210/jcemcr/luad167
primary care? Prim Care Diabetes. 2021;15(1):59-68.
69. Tobaiqy M, Elkout H. Psychiatric adverse events
doi: 10.1016/j.pcd.2020.07.011
associated with semaglutide, liraglutide and tirzepatide:
59. Singh G, Krauthamer M, Bjalme-Evans M. Wegovy A pharmacovigilance analysis of individual case safety
(semaglutide): A new weight loss drug for chronic weight reports submitted to the EudraVigilance database. Int J Clin
management. J Investig Med. 2022;70(1):5-13. Pharm. 2024;46(2):488-495.
doi: 10.1136/jim-2021-001952 doi: 10.1007/s11096-023-01694-7

Volume 2 Issue 1 (2025) 16 doi: 10.36922/imo.4911